# NCT06736327 (NCT06736327)

> A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06736327
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Advanced Solid Tumors
- Interventions: SKB500
- Enrollment: 180
- Primary outcome: Evaluate the incidence of adverse events (AEs)
- Primary outcome: Evaluate the incidence of serious adverse events (SAEs)
- Primary outcome: Evaluate the incidence of treatment related adverse events (TRAEs)
- Primary outcome: Evaluate the incidence of dose-limiting toxicities (DLTs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06736327